评估肺结核的快速诊断检验
|
By LabMedica International staff writers Posted on 02 May 2018 |

图片:Xpert MTB/RIF试剂载入GeneXpert 4模块仪器(图片蒙Cepheid公司惠赐)。
在资源有限的场合诊断涂片阴性肺结核与肺外结核(TB)仍是一项挑战。确认涂片阴性与肺外结核病例需要阳性的结核分枝杆菌培养物,需要长达八周时间制备。
研究人员评估了是否能实现用商用的快速分子诊断检验日常诊断涂片阴性或肺外的结核,评估了其诊断准确度,还评估了现实场合HIV的患病率。
一组来自多国的科学家与瑞士日内瓦大学医院(www.hug-ge.ch)的科学家合作,在两年期间开展了一项前瞻性队列研究,相继纳入了疑似涂片阴性肺结核/肺外结核的所有病例。将病例分为四类:确实、很可能、可能有结核或有其它诊断结果。在马达加斯加的一家当地医院对疑似肺结核患者的痰液样本进行齐尔-尼尔森染色后直接做显微镜检。
来自肺结核患者和肺外结核患者的所有的抗酸杆菌(AFB)阴性涂片都被送到结核分枝杆菌实验室做二次涂片检查、培养,并用美国加利福尼亚州森尼韦尔市Cepheid股份有限公司(www.cepheid.com)的Xpert MTB/RIF进行筛查。生物液(脑脊液、腹膜液、胸腔积液)的标准分析(细胞学分析与生化分析),还对组织样本(淋巴结、皮肤活检样本、胸腔活检样本和滑膜活检样本)做了病理检查。对所有患者进行HIV血清检验。通过三种不同的构象快速检验证实了HIV的状态。
科学家发现,纳入研究的363名患者中,183人(50.4%)有疑似的涂片阴性肺结核,180人(49.6%)有疑似的肺外结核。用Xpert MTB/RIF检测经过证实的病例,灵敏度、特异性、阳性预测值、阴性预测值分别为82.4%、98.8%、98.3%和86.6%;如果把经过证实的病例和可能性大的病例一起算,这些值分别为65%、98.8%、98.5%和64%。肺外结核的诊断准确度略低于涂片阴性的肺结核。HIV感染的患病率为12.1%,但是几乎半数病例没有结核(其它诊断结果组)。
该研究的论文发表于2018年4月号的《国际传染病杂志》(International Journal of Infectious Diseases)。作者总结说,在资源贫乏场合实施结核的快速诊断是可行的。Xpert-MTB/RIF检测难诊人群的性能十分突出。这项研究得出的HIV患病率远高于所报的马达加斯加大众的患病率、结核患者的患病率以及结核以外病症患者的患病率。
日内瓦大学医院>>> www.hug-ge.ch
Cepheid >>> www.cepheid.com
Latest 实验室技术 News
Channels
Clinical Chemistry
view channel
Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read moreMolecular Diagnostics
view channel
Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more
New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







